Literature DB >> 19723143

Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer.

Qi Wang1, Zhi-Guo Chen, Chang-Zheng Du, Hong-Wei Wang, Li Yan, Jin Gu.   

Abstract

AIMS: The CD133 antigen has been identified as a putative stem cell marker in colorectal cancer tissues. According to the cancer stem cell hypothesis, CD133+ cells determine long-term tumour growth and are therefore suspected of influencing clinical outcome. The aim was to investigate the prognostic value of CD133 expression in rectal cancer patients after preoperative radiation and curative resection. METHODS AND
RESULTS: The expression of the CD133 stem cell antigen in a series of 73 patients with rectal cancer of various ypTNM stages was analysed by immunohistochemistry on formalin-fixed paraffin-embedded sections. The prognostic value of CD133 expression and other clinicopathological factors was evaluated. On multivariate survival analysis, the proportion of CD133+ cells was a significant (P < 0.05) prognostic factor for adverse disease-free survival and overall survival independent of ypTNM stage, tumour differentiation or lymphovascular invasion.
CONCLUSIONS: CD133 stem cell antigen expression correlates with patient survival in rectal cancer, lending support to the current cancer stem cell hypothesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19723143     DOI: 10.1111/j.1365-2559.2009.03378.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  30 in total

1.  Correlation of aberrant expression of CD133 with FHIT and malignant phenotype of colorectal adenocarcinoma.

Authors:  Hong Li; Po Zhao; Yang Lu; Yali Lu
Journal:  Int J Colorectal Dis       Date:  2012-02-09       Impact factor: 2.571

Review 2.  Individualization of cancer treatment from radiotherapy perspective.

Authors:  Ala Yaromina; Mechthild Krause; Michael Baumann
Journal:  Mol Oncol       Date:  2012-02-09       Impact factor: 6.603

3.  Formation of spherical cancer stem-like cell colonies with resistance to chemotherapy drugs in the human malignant fibrous histiocytoma NMFH-1 cell line.

Authors:  Liang Deng; Dejian Li; Wenguang Gu; Aiguo Liu; Xiangyang Cheng
Journal:  Oncol Lett       Date:  2015-09-16       Impact factor: 2.967

4.  CD133(+) single cell-derived progenies of colorectal cancer cell line SW480 with different invasive and metastatic potential.

Authors:  Guangqiu Li; Chao Liu; Jian Yuan; Xiaoqin Xiao; Na Tang; Junmei Hao; Hongwei Wang; Xiuwu Bian; Yongjian Deng; Yanqing Ding
Journal:  Clin Exp Metastasis       Date:  2010-07-09       Impact factor: 5.150

5.  Evaluating stem and cancerous biomarkers in CD15+CD44+ KYSE30 cells.

Authors:  Fatemeh B Rassouli; Maryam M Matin; Ahamd Reza Bahrami; Kamran Ghaffarzadegan; Hamid Cheshomi; Sara Lari; Bahram Memar; Mun Seng Kan
Journal:  Tumour Biol       Date:  2013-10

Review 6.  Cancer stem cells and their role in metastasis.

Authors:  Yusuke Shiozawa; Biao Nie; Kenneth J Pienta; Todd M Morgan; Russell S Taichman
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

7.  High-level expression of stem cell marker CD133 in clear cell renal cell carcinoma with favorable prognosis.

Authors:  Kyungeun Kim; Hyojin Ihm; Jae Y Ro; Yong Mee Cho
Journal:  Oncol Lett       Date:  2011-08-02       Impact factor: 2.967

8.  Cancer stem cells in solid tumors: elusive or illusive?

Authors:  Yvonne Welte; James Adjaye; Hans R Lehrach; Christian Ra Regenbrecht
Journal:  Cell Commun Signal       Date:  2010-05-11       Impact factor: 5.712

9.  Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma.

Authors:  Po Zhao; Yazhuo Li; Yali Lu
Journal:  BMC Cancer       Date:  2010-05-20       Impact factor: 4.430

10.  Rapid re-expression of CD133 protein in colorectal cancer cell lines in vitro and in vivo.

Authors:  Susann Peickert; Julia Waurig; Claudia Dittfeld; Antje Dietrich; Yvette Garbe; Lydia Kabus; Michael Baumann; Marian Grade; Thomas Ried; Leoni A Kunz-Schughart
Journal:  Lab Invest       Date:  2012-09-10       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.